The Future of Complex Pharmaceutical Manufacturing

From method analysis to cGMP commercial formulation, USSF guides you seamlessly through each phase of product development to bring your product to market successfully.

Our ability to provide a multi-faceted approach to formulation and cGMP compliance is of critical value to our customers as there are many unknowns through all the stages of the product development process. With extensive experience in research, formulation, analytics and advanced manufacturing, our world-class scientific team understands the challenges and complexities of providing regulatory conforming clinical materials.

FEATURED

Vaccine Program

The SARS-CoV2 pandemic highlighted the need for proven and effective approaches to vaccine development. It is important to note that USSF has been working in partnership with Vaxform to develop vaccines since its inception in 2013.

USSF Vaccine Products

  • SARS‐CoV‐2 oral vaccine (pre-clincal)
  • Group A Strep injectable vaccine
  • Pertussis (Whooping Cough) oral vaccine

US Specialty Formulations’ Covid-19 oral vaccine mentioned in a press conference with congresswoman Susan Wild and Dr. Ashih Jha. Excerpts from the press conference are featured in the video below:

Breaking News

USSF Oral Covid-19 Vaccine Cleared for Phase One Clinical Trials

Allentown, PA, May 25, 2021 — US Specialty Formulations (USSF), a cGMP pharmaceutical manufacturer, and VaxForm, a vaccine development company, announced positive results from pre-clinical safety and immunological studies for their oral-dosage COVID-19 vaccine, demonstrating the formulation is safe to proceed to human clinical trials.

USSF Oral Covid-19 Vaccine Cleared for Phase One Clinical Trials

Read More